OFFICIAL

FAX RECEIVED

JAN 25 1777

GENENTECH GENENTECH

GROUP 1600

GENENTECH GENENTECH GENENTECH 1 DNA Way

South San Francisco, CA 94080-4990

Facsimile: 650-952-9881

Date:

January 22, 1999

To:

Examiner R. Budens

Examining Group: 1648

U.S. Patent and Trademark Office

Washington, D.C.

Fax Number:

(703) 305-3704

From:

Timothy E. Torchia

Patent Agent

Re:

Serial No. 09/103,262

Attorney Docket P0633D2C2

Number of Pages Including this Cover Page: __5__

Attached:

Amendment Transmittal:

1 page

Supplemental Preliminary Amendment _3_ pages

OFFICIAL DOCUMENTS

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contains information from GENENTECH, INC., which is CONFIDENTIAL AND PRIVILEGED This information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this taxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

IF YOU DID NOT RECEIVE ALL OF THE PAGES. PLEASE CALL JOYCE COHEN AT (650) 225 - 3582 AS SOON AS POSSIBLE.

CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this correspondence is being facsimile transmitted to the Assistant Commissioner of Patents Washington, D.C. 20231 on January 22, 1999 by

.IAN 25 1999

OFFICIAL

GROUP 1600

Patent Docket P0633D2C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Phillip W. Berman et al.

Serial No.: 09/103,262

Filed: 23 June 1998

Methods and Compositions for For:

Vaccination Against HIV

Group Art Unit: 1648

Examiner: R. Budens

CERTIFICATE OF PACSIMILE TRANSMISSION

January 22, 1999: Date of Transmission

I hereby cerufy that this correspondence, consisting of an Amendment Transmittal and Supplemental Preliminary Amendment is being facilities tran Budens, Group 1648, U.S. Patent and Trademark Office, Washington, D.C. 20231

SUPPLEMENTAL PRELIMINARY AMENDMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Prior to the examination of the application on its merits, please enter this amendment and consider the application based on the following amendments and remarks.

IN THE CLAIMS

Please amend the claims as follows:

- An antibody, or epitope-binding fragment thereof, which has the characteristics of 19. a monoclonal antibody [collected] selected from the group consisting of 6E10, 13H8, [11G5, 10F6,] and 6D8 produced by hybridomas with ATCC accession numbers CRL 10514, CRL 10510, and CRL 10513, respectively.
- A monoclonal antibody, selected from the group consisting of monoclonal antibodies 20.